Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




United Kingdom to Build a New Cell and Gene Therapy Manufacturing Center

By LabMedica International staff writers
Posted on 04 Jan 2015
The United Kingdom (UK) Cell Therapy Catapult (Guy's Hospital; Great Maze Pond, London, UK) plans to build the new GBP 55-million Cell Therapy manufacturing center in the Stevenage Bioscience Catalyst campus (Stevenage, UK). More...


Cell therapy and gene therapy use a patient's own cells to fight or prevent diseases such as cancer, and can replace the use of drugs or surgery.

The center which will open in 2017, is forecast to generate investment by international companies of GBP 1.2 billion (80% via export) by the year 2020, and up to 150 new jobs. The center will manufacture commercial supplies of advanced therapeutic medicinal products such as gene and cell therapies, as well as late-phase clinical trial equipment. The Cell Therapy Catapult will manage the center.

According to Iain Gray, Chief Executive of United Kingdom Government's Innovate UK (Swindon, Wiltshire, UK), “This is an exciting development for the Cell Therapy Catapult and an important next step in the establishment of the UK as a global manufacturing center for the cell therapy industry.”

Related Links:
Stevenage Bioscience Catalyst campus
Cell Therapy Catapult
Innovate UK



Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
POC Immunoassay Analyzer
Procise DX
New
HPV Test
Allplex HPV28 Detection
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.